Manus to merge with Inscripta.

Inscripta, a life science technology company, agreed to merge with Manus, a biotechnology company. Financial terms were not disclosed. “Industrial biotech is at a turning point and needs to demonstrate execution at scale. This merger brings together two cutting-edge technology and scale-up platforms and an unmatched commercial capability to meet the growing demand for bioalternatives. We are building a future where scalable, sustainable, and commercially viable bioalternatives become the solution,” Ajikumar Parayil, Manus Founder and CEO.